Literature DB >> 17086905

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.

J J Kragt1, F A H van der Linden, J M Nielsen, B M J Uitdehaag, C H Polman.   

Abstract

INTRODUCTION: Quantitative tests of motor function, like the Timed 25-foot Walk (T25FW) and 9-hole Peg Test (9HPT), are increasingly being applied as outcome measures in multiple sclerosis (MS) clinical trials. The quantitative nature of the data has a favorable impact on responsiveness, but the clinical impact of the changes is uncertain. The goal of this study was to assess whether a change on T25FW and 9HPT does indeed have a clinical meaning. This was accomplished by comparing 20% changes on these quantitative measurements to concomitant changes on the Guy's Neurological Disability Scale (GNDS), a scale which measures patient-perceived daily life disability.
METHODS: From a longitudinal database, we selected patients with at least two measurements of T25FW, 9HPT and GNDS with a minimal time interval of 350 days. In those patients who experienced at least a 20% change on T25FW or 9HPT, GNDS score changes were examined more closely.
RESULTS: Of 527 patients, 143 experienced a >20% worsening on their T25FW and 71 on their 9HPT, respectively. Patients with a 20% increase in T25FW or 9HPT had more GNDS worsening than patients without such an increase. GNDS worsening associated with an increase in T25FW was mainly due to an increase in perceived disability related to lower extremity function and fatigue; GNDS worsening associated with an increase in 9HPT was more diffuse with respect to domains involved.
CONCLUSION: Worsening on T25FW or 9HPT has a clinical impact on disability, as perceived by MS patients during daily life functioning.

Entities:  

Mesh:

Year:  2006        PMID: 17086905     DOI: 10.1177/1352458506070768

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  50 in total

1.  Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed.

Authors:  R I Spain; R J St George; A Salarian; M Mancini; J M Wagner; F B Horak; D Bourdette
Journal:  Gait Posture       Date:  2012-01-25       Impact factor: 2.840

Review 2.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

3.  Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Authors:  Myla D Goldman; Robert W Motl; John Scagnelli; John H Pula; Jacob J Sosnoff; Diego Cadavid
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

4.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

5.  Peg-manipulation capabilities during a test of manual dexterity differ for persons with multiple sclerosis and healthy individuals.

Authors:  Awad M Almuklass; Daniel F Feeney; Diba Mani; Landon D Hamilton; Roger M Enoka
Journal:  Exp Brain Res       Date:  2017-08-28       Impact factor: 1.972

6.  The MoSt Project--more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy.

Authors:  Ruggero Capra; Mario Alberto Battaglia; Antonio Gaudioso; Laura Lopes; Damiano Paolicelli; Marco Paoloni; Carlo Pozzilli; Valter Santilli; Claudio Solaro; Maria Trojano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

7.  Postural response latencies are related to balance control during standing and walking in patients with multiple sclerosis.

Authors:  Jessie M Huisinga; Rebecca J St George; Rebecca Spain; Shannon Overs; Fay B Horak
Journal:  Arch Phys Med Rehabil       Date:  2014-01-18       Impact factor: 3.966

Review 8.  Wellness and the Role of Comorbidities in Multiple Sclerosis.

Authors:  Brandon P Moss; Mary R Rensel; Carrie M Hersh
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

9.  Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Authors:  Myla D Goldman; Robert W Motl; Richard A Rudick
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

10.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.